N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients.

BACKGROUND Hypertensive patients develop carotid atherosclerotic plaques with enhanced inflammation. Full-length osteopontin (OPN-FL), a multifunctional protein whose levels are elevated in association with atherosclerosis, is cleaved by thrombin and matrix metalloproteinases to form a C-terminal and a putatively biologically active N-terminal fragment (OPN-C, OPN-N, respectively). We conducted a study to examine whether plaque inflammation in hypertensive patients corresponds to the expression of OPN or of its cleaved forms or both. METHODS We collected 42 carotid plaques from 41 consecutive hypertensive patients during carotid endarterectomy. Plaque tissue was used to measure matrix metalloproteinase-12 (MMP-12) and OPN proteins, and for the classification of plaques as showing low- or high-degree inflammation through histological and immunohistochemical evaluation. RESULTS Fifteen highly inflamed plaques and 27 plaques with characteristics of low-grade inflammation were collected. Moderate to heavy staining for OPN characterized 87% of the plaques with high-degree inflammation but only 44% of those with low-degree inflammation, corresponding to the percentages of plaques that were heavily stained for the macrophage marker CD68 (93% versus 26%, respectively, P < 0.01). Western blot analysis showed that the abundance of OPN-FL and OPN-C was comparable in the two groups. However, the abundance of OPN-N was significantly greater in the highly inflamed plaques (median, 3.8 (range, 0.8-7.3) vs. median, 0.9 (range, 0.2-1.5); P = 0.017, respectively). The abundance of MMP-12 was significantly greater in the high- than in the low-degree plaque inflammation group (4.8 (range 1.9-8.8) vs. 1.1 (range 0.3-1.4), respectively; P = 0.03). CONCLUSIONS The N-terminal fragment of osteopontin, rather than OPN-FL or OPN-C, is associated with carotid plaque inflammation in hypertensive patients. Future studies should assess whether targeting OPN cleavage could present a new approach to preventing high-risk carotid plaques.

[1]  I. Hahntow,et al.  Impact of chronic kidney disease on carotid plaque vulnerability. , 2011, Journal of vascular surgery.

[2]  P. Doevendans,et al.  Local Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular Events , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[3]  A. Dahl,et al.  Soluble CD36 in Plasma Is Increased in Patients With Symptomatic Atherosclerotic Carotid Plaques and Is Related to Plaque Instability , 2008, Stroke.

[4]  G. Lenzi,et al.  Sonographic Carotid Plaque Morphologic Characteristics and Vascular Risk Factors , 2008, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[5]  L. Leung,et al.  Thrombin Hydrolysis of Human Osteopontin Is Dependent on Thrombin Anion-binding Exosites* , 2008, Journal of Biological Chemistry.

[6]  Spyretta Golemati,et al.  The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. , 2008, Journal of vascular surgery.

[7]  L. Liaw,et al.  Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Rudich,et al.  Regulation of Adipocyte Lipolysis by Degradation of the Perilipin Protein , 2007, Journal of Biological Chemistry.

[9]  M. Stumvoll,et al.  Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. , 2007, Endocrinology.

[10]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[11]  J. Higaki,et al.  Osteopontin and carotid atherosclerosis in patients with essential hypertension. , 2006, Clinical science.

[12]  A. Loewy,et al.  An Osteopontin–NADPH Oxidase Signaling Cascade Promotes Pro–Matrix Metalloproteinase 9 Activation in Aortic Mesenchymal Cells , 2006, Circulation research.

[13]  L. Liaw,et al.  Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[14]  JonathanGolledge,et al.  Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis , 2004 .

[15]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[16]  W. Hsueh,et al.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. , 2003, The Journal of clinical investigation.

[17]  J. Whitworth,et al.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.

[18]  L. Liaw,et al.  Alterations of Arterial Physiology in Osteopontin-Null Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Murakami,et al.  Development of atherosclerosis in osteopontin transgenic mice , 2002, Heart and Vessels.

[20]  M. Noda,et al.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. , 2001, The Journal of clinical investigation.

[21]  M. Noda,et al.  Osteopontin expression and function: Role in bone remodeling , 1998, Journal of cellular biochemistry. Supplement.

[22]  L. Water,et al.  Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. , 1994, Molecular biology of the cell.

[23]  W. Butler,et al.  The nature and significance of osteopontin. , 1989, Connective tissue research.